Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Wojciech Jelski & Barbara Mroczko. (2020) Biochemical Markers of Colorectal Cancer – Present and Future. Cancer Management and Research 12, pages 4789-4797.
Read now
Read now
Eva Sipos, Nikoletta Dobos, David Rozsa, Klara Fodor, Gabor Olah, Zsuzsanna Szabo, Lorant Szekvolgyi, Andrew V Schally & Gabor Halmos. (2018) Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines. OncoTargets and Therapy 11, pages 933-941.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:3.
Read now
Read now
Benjamin A Gartrell & Guru Sonpavde. (2013) Emerging drugs for urothelial carcinoma. Expert Opinion on Emerging Drugs 18:4, pages 477-494.
Read now
Read now
Ferenc G Rick, Norman L Block & Andrew V Schally. (2013) Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opinion on Pharmacotherapy 14:16, pages 2237-2247.
Read now
Read now
Articles from other publishers (76)
Hsien-Ming Wu, Liang-Hsuan Chen, Hong-Yuan Huang, Hsin-Shih Wang & Chia-Lung Tsai. (2023) EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling. International Journal of Molecular Sciences 24:20, pages 15271.
Crossref
Crossref
Georgia Biniari, Christos Markatos, Agathi Nteli, Haralambos Tzoupis, Carmen Simal, Alexios Vlamis-Gardikas, Vlasios Karageorgos, Ioannis Pirmettis, Panagiota Petrou, Maria Venihaki, George Liapakis & Theodore Tselios. (2023) Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer. International Journal of Molecular Sciences 24:20, pages 15232.
Crossref
Crossref
Lavinia Casati, Samuele Ciceri, Roberto Maggi & Daniele Bottai. (2023) Physiological and pharmacological overview of the gonadotropin releasing hormone. Biochemical Pharmacology 212, pages 115553.
Crossref
Crossref
Maritza P. Garrido, Andrea Hernandez, Margarita Vega, Eyleen Araya & Carmen Romero. (2023) Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers. Frontiers in Endocrinology 14.
Crossref
Crossref
Mo Wu, Wei Huang, Nan Yang & Yanyong Liu. (2022) Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
I. V. Maiborodin, A. K. Pichigina, V. I. Maiborodina & E. L. Lushnikova. (2022) Physiological Aspects of the Application of Gonadotropin-Releasing Hormone Agonists in Clinical and Experimental Obstetrics and Gynecology. Journal of Evolutionary Biochemistry and Physiology 58:6, pages 1865-1878.
Crossref
Crossref
Jannik Paulus & Norbert Sewald. (2022) Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin αVβ3. Frontiers in Chemistry 10.
Crossref
Crossref
Goknur Kara, George A. Calin & Bulent Ozpolat. (2022) RNAi-based therapeutics and tumor targeted delivery in cancer. Advanced Drug Delivery Reviews 182, pages 114113.
Crossref
Crossref
Dianna Truong, Nelson Y. S. Lam, Meder Kamalov, Mie Riisom, Stephen M. F. Jamieson, Paul W. R. Harris, Margaret A. Brimble, Nils Metzler‐Nolte & Christian G. Hartinger. (2022) A Solid Support‐Based Synthetic Strategy for the Site‐Selective Functionalization of Peptides with Organometallic Half‐Sandwich Moieties. Chemistry – A European Journal 28:12.
Crossref
Crossref
Simona D’Aguanno, Fabiana Mallone, Marco Marenco, Donatella Del Bufalo & Antonietta Moramarco. (2021) Hypoxia-dependent drivers of melanoma progression. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Fabrizio Fontana & Patrizia Limonta. (2021) Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells 10:5, pages 1133.
Crossref
Crossref
Lital Cohen, Yoav D. Livney & Yehuda G. Assaraf. (2021) Targeted nanomedicine modalities for prostate cancer treatment. Drug Resistance Updates 56, pages 100762.
Crossref
Crossref
Tarun Kumar Patel, Nilanjan Adhikari, Sk. Abdul Amin, Swati Biswas, Tarun Jha & Balaram Ghosh. (2021) Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery. New Journal of Chemistry 45:12, pages 5291-5321.
Crossref
Crossref
Manisha Miller, Lynn Schoenfield, Mohamed Abdel-Rahman & Colleen M. Cebulla. (2021) Is Uveal Melanoma a Hormonally Sensitive Cancer? A Review of the Impact of Sex Hormones and Pregnancy on Uveal Melanoma. Ocular Oncology and Pathology 7:4, pages 239-250.
Crossref
Crossref
Sanyog Jain, Kaisar Raza, Ashish Kumar Agrawal & Ankur Vaidya. 2021. Nanotechnology Applications for Cancer Chemotherapy. Nanotechnology Applications for Cancer Chemotherapy
515
545
.
Fabrizio Fontana, Monica Marzagalli, Marina Montagnani Marelli, Michela Raimondi, Roberta Moretti & Patrizia Limonta. (2020) Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. International Journal of Molecular Sciences 21:24, pages 9511.
Crossref
Crossref
Saba Yasir, Gustavo Fernandez-Castro, Numra Aslam Bajwa, Norman Block, Andrew Schally, Richard Cote & Merce Jorda. (2020) Immunohistochemical expression of receptors for luteinizing hormone-releasing hormone (LHRHR) in muscle-invasive Urothelial carcinoma of urinary bladder: a potential predictive marker for targeted cytotoxic LHRH hybrid analogs. Surgical and Experimental Pathology 3:1.
Crossref
Crossref
J. D. Obayemi, A. A. Salifu, S. C. Eluu, V. O. Uzonwanne, S. M. Jusu, C. C. Nwazojie, C. E. Onyekanne, O. Ojelabi, L. Payne, C. M. Moore, J. A. King & W. O. Soboyejo. (2020) LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer. Scientific Reports 10:1.
Crossref
Crossref
Klara Fodor, Nikoletta Dobos, Andrew Schally, Zita Steiber, Gabor Olah, Eva Sipos, Lorant Szekvolgyi & Gabor Halmos. (2020) The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma. Oncotarget 11:2, pages 175-187.
Crossref
Crossref
Advaita Ganguly, Kumakshi Sharma & Kaustav Majumder. 2020. Biopolymer-Based Formulations. Biopolymer-Based Formulations
87
104
.
Murányi, Varga, Gyulavári, Pénzes, Németh, Csala, Pethő, Csámpai, Halmos, Peták & Vályi-Nagy. (2019) Novel Crizotinib–GnRH conjugates revealed the significance of lysosomal trapping in GnRH-based drug delivery systems. International Journal of Molecular Sciences 20:22, pages 5590.
Crossref
Crossref
J. Delahousse, C. Skarbek & A. Paci. (2019) Prodrugs as drug delivery system in oncology. Cancer Chemotherapy and Pharmacology 84:5, pages 937-958.
Crossref
Crossref
Lilla Pethő, József Murányi, Kinga Pénzes, Bianka Gurbi, Diána Brauswetter, Gábor Halmos, Gabriella Csík & Gábor Mező. (2019) Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers. International Journal of Molecular Sciences 20:20, pages 5027.
Crossref
Crossref
Maira Huerta-Reyes, Guadalupe Maya-Núñez, Marco Allán Pérez-Solis, Eunice López-Muñoz, Nancy Guillén, Jean-Christophe Olivo-Marin & Arturo Aguilar-Rojas. (2019) Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Frontiers in Oncology 9.
Crossref
Crossref
Philipp Klahn, Verena Fetz, Antje Ritter, Wera Collisi, Bettina Hinkelmann, Tatjana Arnold, Werner Tegge, Katharina RoxStephan Hüttel, Kathrin I. Mohr, Joachim Wink, Marc Stadler, Josef Wissing, Lothar Jänsch & Mark Brönstrup. (2019) The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates. Chemical Science 10:20, pages 5197-5210.
Crossref
Crossref
Rongjun He, Brian Finan, John P. Mayer & Richard D. DiMarchi. (2019) Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules 24:10, pages 1855.
Crossref
Crossref
Jyoti Roy, Miranda Kaake & Philip S. Low. (2019) Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers. Oncotarget 10:2, pages 152-160.
Crossref
Crossref
Sabine Schuster, Beáta Biri-Kovács, Bálint Szeder, László Buday, János Gardi, Zsuzsanna Szabó, Gábor Halmos & Gábor Mező. (2018) Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification. Pharmaceutics 10:4, pages 223.
Crossref
Crossref
Gábor Oláh, Nikoletta Dobos, György Vámosi, Zsuzsanna Szabó, Éva Sipos, Klára Fodor, Kristóf Harda, Andrew V. Schally & Gábor Halmos. (2018) Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). European Journal of Pharmaceutical Sciences 123, pages 371-376.
Crossref
Crossref
Canan Schumann, Stephanie Chan, Jess A. Millar, Yuliya Bortnyak, Katherine Carey, Alex Fedchyk, Leon Wong, Tetiana Korzun, Abraham S. Moses, Anna Lorenz, Delany Shea, Olena Taratula, Oleh Khalimonchuk & Oleh Taratula. (2018) Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. Nanomedicine: Nanotechnology, Biology and Medicine 14:4, pages 1395-1405.
Crossref
Crossref
Eirinaios I Vrettos, Gábor Mező & Andreas G Tzakos. (2018) On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein Journal of Organic Chemistry 14, pages 930-954.
Crossref
Crossref
Sabine Schuster, Beáta Biri-Kovács, Bálint Szeder, Viktor Farkas, László Buday, Zsuzsanna Szabó, Gábor Halmos & Gábor Mező. (2018) Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery. Beilstein Journal of Organic Chemistry 14, pages 756-771.
Crossref
Crossref
Yasar Hoosen, Priyamvada Pradeep, Pradeep Kumar, Lisa Du Toit, Yahya Choonara & Viness Pillay. (2018) Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention. International Journal of Molecular Sciences 19:3, pages 731.
Crossref
Crossref
Antoine Henninot, James C. Collins & John M. Nuss. (2017) The Current State of Peptide Drug Discovery: Back to the Future?. Journal of Medicinal Chemistry 61:4, pages 1382-1414.
Crossref
Crossref
Chang Yu, Binbin Ding, Xinyang Zhang, Xiaoran Deng, Kerong Deng, Ziyong Cheng, Bengang Xing, Dayong Jin, Ping'an Ma & Jun Lin. (2018) Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo. Biomaterials 155, pages 112-123.
Crossref
Crossref
Sepideh Khazeni & Pegah Varamini. 2018. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Dominic Agyei, Kei-Xian Tan, Sharadwata Pan, Chibuike C. Udenigwe & Michael K. Danquah. 2018. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Peptide Applications in Biomedicine, Biotechnology and Bioengineering
231
251
.
Silvia Paola Corona, Giandomenico Roviello, Carla Strina, Manuela Milani, Giovanni Allevi, Sergio Aguggini, Daniele Zanoni & Daniele Generali. (2017) Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?. Future Oncology 13:27, pages 2473-2477.
Crossref
Crossref
Kathryn L. Garner, Krasimira Tsaneva-Atanasova & Craig A. McArdle. 2017. Endocrinology of the Testis and Male Reproduction. Endocrinology of the Testis and Male Reproduction
35
70
.
Tao Liu & Qianxia Huang. (2016) Biodegradable brush-type copolymer modified with targeting peptide as a nanoscopic platform for targeting drug delivery to treat castration-resistant prostate cancer. International Journal of Pharmaceutics 511:2, pages 1002-1011.
Crossref
Crossref
ANNA M. CZARNECKA, MAGDALENA NIEDZWIEDZKA, CAMILLO PORTA & CEZARY SZCZYLIK. (2016) Hormone signaling pathways as treatment targets in renal cell cancer (Review). International Journal of Oncology 48:6, pages 2221-2235.
Crossref
Crossref
Chun-Jui Lin, Chen-Hsiang Kuan, Li-Wen Wang, Hsi-Chin Wu, Yunching Chen, Chien-Wen Chang, Rih-Yang Huang & Tzu-Wei Wang. (2016) Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics. Biomaterials 90, pages 12-26.
Crossref
Crossref
Yosi Gilad, Michael Firer & Gary Gellerman. (2016) Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. Biomedicines 4:2, pages 11.
Crossref
Crossref
Fan Yang, Weilun Ai, Fagang Jiang, Xin Liu, Zebo Huang & Shibin Ai. (2016) Preclinical Evaluation of an Epidermal Growth Factor Receptor–Targeted Doxorubicin–Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice. Journal of Pharmaceutical Sciences 105:2, pages 639-649.
Crossref
Crossref
Kathryn L. Garner, Krasimira Tsaneva-Atanasova & Craig A. McArdle. 2016. Endocrinology of the Testis and Male Reproduction. Endocrinology of the Testis and Male Reproduction
1
36
.
Hamdy A. Azim & Hatem A. AzimJr.Jr.. (2015) Potential Therapeutic Targets in Triple Negative Breast Cancer. Current Breast Cancer Reports 7:4, pages 215-223.
Crossref
Crossref
Ferenc G. Rick & Andrew V. Schally. (2015) Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 33:6, pages 270-274.
Crossref
Crossref
Hsien-Ming Wu, Hong-Yuan Huang, Chyi-Long Lee, Yung-Kuei Soong, Peter C.K. Leung & Hsin-Shih Wang. (2015) Gonadotropin-Releasing Hormone Type II (GnRH-II) Agonist Regulates the Motility of Human Decidual Endometrial Stromal Cells: Possible Effect on Embryo Implantation and Pregnancy1. Biology of Reproduction 92:4.
Crossref
Crossref
M. Gizzi, P. Pautier, C. Lhomme & A. Leary. (2015) Novel membrane-based targets ? Therapeutic potential in gynecological cancers. Critical Reviews in Oncology/Hematology 93:3, pages 293-303.
Crossref
Crossref
Mingliang Fan, Danbo Yang, Xiaofei Liang, Junping Ao, Zonghai Li, Hongyang Wang & Bizhi Shi. (2015) Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Biomedicine & Pharmacotherapy 70, pages 268-273.
Crossref
Crossref
Shan Wu, Jinsong Guo, Wendong Wei, Jue Zhang, Jing Fang & Stephen J Beebe. (2014) Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine. Cancer Cell International 14:1.
Crossref
Crossref
Stephan Seitz, Stefan Buchholz, Andrew Victor Schally, Florian Weber, Monika Klinkhammer-Schalke, Elisabeth C Inwald, Roberto Perez, Ferenc G Rick, Luca Szalontay, Florian Hohla, Sabine Segerer, Chui Wai Kwok, Olaf Ortmann & Jörg Bernhard Engel. (2014) Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer 14:1.
Crossref
Crossref
Rachel Stephenson, Pegah Varamini, Neville Butcher, Rodney Minchin & Istvan Toth. (2014) Effect of lipidated gonadotropin-releasing hormone peptides on receptor mediated binding and uptake into prostate cancer cells in vitro. Nanomedicine: Nanotechnology, Biology and Medicine 10:8, pages 1799-1808.
Crossref
Crossref
Marina Montagnani Marelli, Marilena Manea, Roberta Moretti, Monica Marzagalli & Patrizia Limonta. (2014) Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. International Journal of Oncology.
Crossref
Crossref
Di Wen, Deepak Chitkara, Hao Wu, Michael Danquah, Renukadevi Patil, Duane D. Miller & Ram I. Mahato. (2014) LHRH-Conjugated Micelles for Targeted Delivery of Antiandrogen to Treat Advanced Prostate Cancer. Pharmaceutical Research 31:10, pages 2784-2795.
Crossref
Crossref
Ya-Xiong TaoP. Michael Conn. (2014) Chaperoning G Protein-Coupled Receptors: From Cell Biology to Therapeutics. Endocrine Reviews 35:4, pages 602-647.
Crossref
Crossref
Ashutosh Barve, Wei Jin & Kun Cheng. (2014) Prostate cancer relevant antigens and enzymes for targeted drug delivery. Journal of Controlled Release 187, pages 118-132.
Crossref
Crossref
Omar N. AkramDavid J. DeGraff, Jonathan H. SheehanWayne D. Tilley, Robert J. MatusikJung-Mo AhnGanesh V. Raj. (2014) Tailoring Peptidomimetics for Targeting Protein–Protein Interactions. Molecular Cancer Research 12:7, pages 967-978.
Crossref
Crossref
P. Michael ConnEmery SmithTimothy SpicerPeter ChaseLouis ScampaviaJo Ann Janovick. (2014) A Phenotypic High Throughput Screening Assay for the Identification of Pharmacoperones for the Gonadotropin Releasing Hormone Receptor. ASSAY and Drug Development Technologies 12:4, pages 238-246.
Crossref
Crossref
Kelly K. Curtis, John Sarantopoulos, Donald W. Northfelt, Glen J. Weiss, Kerry M. Barnhart, John K. Whisnant, Carola Leuschner, Hector Alila, Mitesh J. Borad & Ramesh K. Ramanathan. (2014) Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemotherapy and Pharmacology 73:5, pages 931-941.
Crossref
Crossref
Theodoros Karampelas, Orestis Argyros, Nisar Sayyad, Katerina Spyridaki, Charalampos Pappas, Kevin Morgan, George Kolios, Robert P Millar, George Liapakis, Andreas G. Tzakos, Demosthenes Fokas & Constantin Tamvakopoulos. (2014) GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery. Bioconjugate Chemistry 25:4, pages 813-823.
Crossref
Crossref
Verena Natalie Schreier, Lilla Peth?Erika Orb?n, Andreas Marquardt, Brindusa Alina Petre, G?bor Mez?Marilena Manea. (2014) Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate. PLoS ONE 9:4, pages e94041.
Crossref
Crossref
Miklos JaszberenyiFerenc G. Rick, Petra PopovicsNorman L. Block, Marta ZarandiRen-Zhi CaiIrving VidaurreLuca SzalontayArumugam R. JayakumarAndrew V. Schally. (2013) Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proceedings of the National Academy of Sciences 111:2, pages 781-786.
Crossref
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Crossref
Naruemon Pratanwanich & Pietro Li?. (2014) Pathway-based Bayesian inference of drug?disease interactions. Mol. BioSyst. 10:6, pages 1538-1548.
Crossref
Crossref
Gregory T. Notte. 2014.
417
436
.
Hsien-Ming Wu, Hsin-Shih Wang, Hong-Yuan Huang, Chyong-Huey Lai, Chyi-Long Lee, Yung-Kuei Soong & Peter CK Leung. (2013) Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2. BMC Cancer 13:1.
Crossref
Crossref
Gábor Mezo. 2013. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins
203
252
.
Patrizia Limonta & Marilena Manea. (2013) Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treatment Reviews 39:6, pages 647-663.
Crossref
Crossref
Allan A. Kaspar & Janice M. Reichert. (2013) Future directions for peptide therapeutics development. Drug Discovery Today 18:17-18, pages 807-817.
Crossref
Crossref
Karoly Szepeshazi, Andrew V. Schally, Norman L. Block, Gabor Halmos, Mehrdad Nadji, Luca Szalontay, Irving Vidaurre, Andrew Abi-Chaker & Ferenc G. Rick. (2013) Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108. Oncotarget 4:5, pages 751-760.
Crossref
Crossref
C.G. Ziegler, M. Ullrich, A.V. Schally, R. Bergmann, J. Pietzsch, L. Gebauer, K. Gondek, N. Qin, K. Pacak, M. Ehrhart-Bornstein, G. Eisenhofer & S.R. Bornstein. (2013) Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells. Molecular and Cellular Endocrinology 371:1-2, pages 189-194.
Crossref
Crossref
Verena Natalie Schreier, Gábor Mező, Erika Orbán, Claudia Dürr, Andreas Marquardt & Marilena Manea. (2013) Synthesis, enzymatic stability and in vitro cytostatic effect of Daunorubicin-GnRH-III derivative dimers. Bioorganic & Medicinal Chemistry Letters 23:7, pages 2145-2150.
Crossref
Crossref
Miklos Jaszberenyi, Andrew V. Schally, Norman L. Block, Mehrdad Nadji, Irving Vidaurre, Luca Szalontay & Ferenc G. Rick. (2013) Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget 4:3, pages 422-432.
Crossref
Crossref
Wei-Liang Ye, Zeng-Hui Teng, Dao-Zhou Liu, Han Cui, Miao Liu, Ying Cheng, Tie-Hong Yang, Qi-Bing Mei & Si-Yuan Zhou. (2013) Synthesis of a New pH-Sensitive Folate–Doxorubicin Conjugate and its Antitumor Activity In Vitro. Journal of Pharmaceutical Sciences 102:2, pages 530-540.
Crossref
Crossref
Karoly Szepeshazi, Andrew V. Schally, Gunhild Keller, Norman L. Block, Daniel Benten, Gabor Halmos, Luca Szalontay, Irving Vidaurre, Miklos Jaszberenyi & Ferenc G. Rick. (2012) Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). Oncotarget 3:7, pages 686-699.
Crossref
Crossref